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Cellular attachment factors like the C-type lectins DC-SIGN and DC-SIGNR (collectively referred to as DC-SIGN/R) can augment viral
infection and might promote viral dissemination in and between hosts. The lectin LSECtin is encoded in the same chromosomal locus as DC-
SIGN/R and is coexpressed with DC-SIGNR on sinusoidal endothelial cells in liver and lymphnodes. Here, we show that LSECtin enhances
infection driven by filovirus glycoproteins (GP) and the S protein of SARS coronavirus, but does not interact with human immunodeficiency
virus type-1 and hepatitis C virus envelope proteins. Ligand binding to LSECtin was inhibited by EGTA but not by mannan, suggesting that
LSECtin unlike DC-SIGN/R does not recognize high-mannose glycans on viral GPs. Finally, we demonstrate that LSECtin is N-linked
glycosylated and that glycosylation is required for cell surface expression. In summary, we identified LSECtin as an attachment factor that in
conjunction with DC-SIGNR might concentrate viral pathogens in liver and lymph nodes.
D 2005 Elsevier Inc. All rights reserved.Keywords: Ebolavirus; SARS coronavirus; Human immunodeficiency virus; Hepatitis C virus; LSECtin; DC-SIGN; DC-SIGNR; Attachment factor; Receptor;
GlycoproteinIntroduction
The membrane glycoproteins (GP) of enveloped viruses
facilitate infection of target cells through the interaction with
cellular receptors. However, binding of virions to target cells
is not necessarily mediated by GP interactions with receptor,
but can be facilitated by GP binding to attachment factors.0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.06.026
* Corresponding author. Nikolaus-Fiebiger-Center, University Erlangen-
Nu¨rnberg, Glu¨ckstraße 6, 91054 Erlangen, Germany. Fax: +49 9131
8529111.
E-mail address: snpoehlm@viro.med.uni-erlangen.de (S. Po¨hlmann).Attachment factor engagement is not sufficient to allow
infectious entry, but can augment infection. Several cellular
lectins can serve as attachment factors. Thus, dendritic cell
specific intercellular adhesion molecule-3 grabbing non-
integrin (DC-SIGN), a C-type (calcium dependent) lectin
which is expressed at high levels on dendritic cells (DCs),
binds human immunodeficiency virus (HIV) envelope
protein (Env) and promotes viral transfer to susceptible
cells (‘‘infection in trans’’) (Geijtenbeek et al., 2000). DC-
SIGN-mediated HIV infection in trans could aid viral
dissemination upon sexual transmission of HIV (Geijten-
beek et al., 2000). Besides HIV, DC-SIGN interacts with a05) 224 – 236
T. Gramberg et al. / Virology 340 (2005) 224–236 225range of other viral (Alvarez et al., 2002; Gardner et al.,
2003; Halary et al., 2002; Klimstra et al., 2003; Lozach et
al., 2003, 2004; Marzi et al., 2004; Navarro-Sanchez et al.,
2003; Po¨hlmann et al., 2003; Simmons et al., 2003;
Tassaneetrithep et al., 2003; Yang et al., 2004) and non-
viral pathogens (Van Kooyk and Geijtenbeek, 2003), which
use DC-SIGN to target DCs. Notably, DC-SIGN-mediated
enhancement of HIV infection is not limited to concentrat-
ing viral particles onto the cell surface (Po¨hlmann et al.,
2001b), but involves internalization and complex intra-
cellular trafficking of virions (Kwon et al., 2002; McDonald
et al., 2003).
The lectin DC-SIGNR (also known as L-SIGN) shares
77% amino acid identity with DC-SIGN and also interacts
with pathogens (Bashirova et al., 2001; Mummidi et al.,
2001; Po¨hlmann et al., 2001c). DC-SIGNR is expressed on
sinusoidal endothelial cells in lymph nodes and liver
(Bashirova et al., 2001; Mummidi et al., 2001; Po¨hlmann
et al., 2001c), and the latter cell type shares several features
with DCs (Limmer et al., 2000). Liver sinusoidal endothelial
cells (LSECs) have been implicated in transmission of duck
hepatitis B virus (DHBV) to adjacent hepatocytes, a process
that involves endocytosis and intracellular transport of viral
particles (Breiner et al., 2001). Enhancement of viral in-
fection by LSECs and DCs might involve similar pathways,
and hepatotropic viruses might specifically target LSECs to
promote their spread in liver tissue (Breiner et al., 2001).
DC-SIGN and DC-SIGNR (collectively referred to as
DC-SIGN/R) recognize high-mannose carbohydrates on the
surface of ligands (Appelmelk et al., 2003; Feinberg et al.,
2001; Lin et al., 2003), and albeit a role for protein–protein
contacts in the interaction of DC-SIGN with HIV has been
reported (Geijtenbeek et al., 2002), a large body of evidence
suggests that carbohydrate recognition is the sole determi-
nant of DC-SIGN/R ligand specificity (Appelmelk et al.,
2003; Feinberg et al., 2001; Guo et al., 2004; Lin et al.,
2003). In fact, while DC-SIGNR is strictly high-mannose
carbohydrate specific, DC-SIGN can interact with other
carbohydrates. These differences in carbohydrate specificity
account for differences in the ligand spectrum of these
lectins (Guo et al., 2004; Van Liempt et al., 2004).
Recently, LSECtin (liver and lymph node sinusoidal
endothelial cell C-type lectin), a lectin which is coexpressed
with DC-SIGNR on sinusoidal endothelial cells in liver and
lymph node has been identified (Liu et al., 2004). The
LSECtin gene is located on chromosome 19p13.3 in the
vicinity of the genes encoding DC-SIGN/R and CD23 (Liu et
al., 2004). Sequence analysis revealed that LSECtin harbors
all invariant and most of the highly conserved amino acid
residues characteristic for C-type lectins (Liu et al., 2004).
The carbohydrate recognition domain (CRD) of LSECtin
exhibits 39% and 38% amino acid sequence identity with the
respective domains of DC-SIGN/R and was shown to
interact with various carbohydrates, including mannose, N-
acetylglucosamine (GlcNAc), and fucose (Liu et al., 2004).
However, the ligand(s) of this lectin are unknown.Here, we demonstrate that LSECtin interacts with the
GPs of filoviruses and the spike (S) protein of the severe
acute respiratory syndrome (SARS) coronavirus (CoV) and
enhances viral infection. Augmentation of filovirus infec-
tion was observed with lentiviral pseudotypes bearing
filovirus GPs and with replication-competent Ebolavirus of
the Zaire strain (ZEBOV), indicating that LSECtin might
promote filovirus infection in vivo. In contrast, LSECtin
did not functionally interact with HIV and hepatitis C virus
(HCV) Env proteins. LSECtin interactions with viral GPs
were dependent on calcium, but were not blocked by
mannan, indicating that LSECtin and DC-SIGN/R might
differ in their carbohydrate specificities. Finally, we present
evidence that LSECtin is N-linked glycosylated and that
glycosylation is important for cells surface expression.Results
Regulated expression of LSECtin on a 293 cell line and
endogenous expression on LSECs
The LSECtin ORF was amplified from liver RNA,
cloned, and 293 cell lines expressing the lectin upon
induction with doxycycline were generated as described
(Po¨hlmann et al., 2001a). Alternatively, LSECtin was
transiently expressed in 293T cells. LSECtin expression
was verified with an antiserum generated by immunization
of mice with a GST-LSECtin fusion protein produced in
bacteria. FACS analysis revealed that serum from immu-
nized mice, but not serum obtained prior to immunization,
reacted with cells induced to express LSECtin (Figs. 1B, E).
In contrast, no reactivity was observed with uninduced cells
(Fig. 1A) or cells expressing DC-SIGN or DC-SIGNR
(Figs. 1C, D), indicating that reactivity was specific and that
LSECtin was expressed at the cell surface to appreciable
levels and in a regulated fashion. Similar levels of LSECtin
expression were also obtained with transiently transfected
293T cells (data not shown). LSECtin expression in LSEC
has previously been demonstrated by immunofluorescence
analysis of tissue sections (Liu et al., 2004). We employed
the LSECtin specific mouse serum to investigate if LSECtin
is expressed on the surface of primary LSECs obtained from
human liver tissue. Analysis of LSECs obtained from three
different donors revealed readily detectable surface expres-
sion of LSECtin (Fig. 1F), suggesting that this lectin might
contribute to the recognition of blood-borne antigens by
LSECs.
LSECtin expression augments infection driven by filovirus
GPs and the S protein of SARS-CoV
We first investigated if LSECtin expression enhances
infection by lentiviral luciferase reporter viruses bearing the
GPs of ZEBOV, Marburgvirus (MARV), Lassa virus,
SARS-CoV, murine leukemia virus (MLV), and vesicular
Fig. 1. Inducible expression of LSECtin on 293 T-REx cells and endogenous expression on LSEC. (A–E) Regulated LSECtin expression on cell lines. Cell
lines were generated by stable transfection and lectin expression was analyzed with an antiserum raised against a GST-LSECtin fusion protein (A–D) or with
pre-immune serum (E). Lectin expression on doxycycline (dox)-induced LSECtin T-REx cells (black) was compared to the following cells (white): (A)
uninduced LSECtin T-REx cells, (B and E) induced T-REx control cells, (C) induced DC-SIGN T-REx cells, (D) induced DC-SIGNR T-REx cells. (F)
Expression of LSECtin on LSECs. Primary human LSECs were obtained from human liver tissue and analyzed for LSECtin expression as described above.
Similar results were obtained with cells from three different donors.
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analyzed with 293T cells as targets, since these cells are
permissive to infectious cellular entry driven by the above
listed GPs. Virus stocks were generated as described
(Simmons et al., 2003), normalized for comparable lucifer-
ase production upon infection of untransfected 293T control
cells, and used for infection of 293T cells transiently
expressing DC-SIGN/R, LSECtin, or empty vector (Fig.
2A). Infection is shown relative to infectious entry into
control cells, which was set as 100%. In agreement with
previous reports (Alvarez et al., 2002; Jeffers et al., 2004;
Marzi et al., 2004; Simmons et al., 2003; Yang et al., 2004),
expression of DC-SIGN/R strongly augmented infection
driven by filovirus GPs and the SARS-CoV-S protein, but
had no appreciable effect on infectious entry mediated by
VSV-, MLV-, and Lassa-GP (Fig. 2A). Expression of
LSECtin enhanced filovirus GP driven infection with high
efficiency and moderately augmented entry by SARS-CoV-
S bearing reporter viruses (Fig. 2A). LSECtin expression on
non-permissive HeLa cells did not render these cells
susceptible to SARS-CoV-S bearing pseudotypes. In con-
trast, expression of the SARS-CoV receptor ACE2 (Li et al.,
2003) allowed for efficient infection and infectious entry
was enhanced upon coexpression of LSECtin (Fig. 2B),
indicating that LSECtin functions as an attachment factor,
but not as a viral receptor. Comparable results were obtained
for DC-SIGN (data not shown), and these observations are
in agreement with our previously published results (Marziet al., 2004). Antiserum raised against LSECtin abrogated
LSECtin-, but not DC-SIGN-mediated enhancement of
ZEBOV-GP driven infection (Fig. 2C), and augmentation
of infection was dependent on induction of lectin
expression (data not shown), confirming that enhanced
infection was indeed due to LSECtin expression. Thus,
LSECtin joins DC-SIGN/R as a potent attachment factor
which augments infection driven by certain viral GPs.
LSECtin does not interact with HIV-1 and pseudotypes
bearing hepatitis C virus envelope proteins
LSECs have been shown to bind HCV E2 protein
(Ludwig et al., 2004) and to be permissive to HIV infection
(Steffan et al., 1992). We therefore investigated if these
viruses engage LSECtin. In order to assess if LSECtin
interacts with HIV-1, T-REx cell lines were induced to
express the indicated lectins, pulsed with replication-
competent HIV-1 NL4-3 harboring the luciferase gene in
place of nef (Po¨hlmann et al., 2001a), washed three times,
and either lysed or cocultivated with CEMx174 5.25 target
cells. The content of bound virions in cell lysates was
measured by p24 antigen capture ELISA, while trans-
mission to target cells was determined 3 days after
cocultivation by assessing luciferase activity in cell lysates.
Cells expressing DC-SIGN bound and transmitted HIV-1
about 10-fold more efficiently than control cells and the
interaction was inhibited by mannan (Fig. 3A). In contrast,
Fig. 2. Impact of LSECtin expression on viral infection. (A) LSECtin and DC-SIGN/R augment infection by lentiviral pseudotypes bearing filovirus GPs
or SARS-CoV-S. Lentiviral pseudotypes harboring the GPs of the indicated viruses were normalized for comparable infection of 293T control cells and
used to infect 293T cells transiently expressing DC-SIGN/R, LSECtin, or empty vector. The reporter viruses employed contain the luciferase gene, which
is expressed only upon integration of the proviral DNA into the cellular genome. Three days after infection, the cells were lysed and luciferase activity
was determined. Infection is shown relative to infectious entry into control cells, which was set as 100%. Upon infection of control cells with ZEBOV-GP,
SARS-CoV-S, or VSV-G bearing pseudotypes, luciferase activities of 9049 T 1546, 19,810 T 6809, and 6341 T 676 counts per second (c.p.s.) were
measured. The result of a representative experiment is shown, similar results were obtained in three independent experiments. Error bars indicate standard
deviation (SD). (B) LSECtin expression does not allow SARS-CoV-S driven infection of non-permissive cells. HeLa cells, which do not express the
SARS-CoV receptor ACE2 and are refractory to SARS-CoV-S driven infection, were transiently transfected with LSECtin or ACE2 or cotransfected with
both plasmids. The transfected cells were subsequently infected with SARS-CoV-S bearing pseudotypes and luciferase activity was determined as
described under panel A. The results of a representative experiment performed in quadruplicates are shown, error bars indicate SD. Similar results were
obtained in two independent experiments. (C) Inhibition of infection by LSECtin-specific antiserum. T-REx cell lines were induced to express DC-SIGN
or LSECtin, incubated with LSECtin-specific antiserum and infected with ZEBOV-GP harboring pseudotypes, which were normalized for equal luciferase
activity upon infection of control cells. A representative experiment is shown, error bars indicate SD. Similar results were obtained in an independent
experiment.
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similar to that observed with control cells (Fig. 3A),
indicating that LSECtin does not interact with HIV-1.
LSECtin interactions with infectious lentiviral particles
bearing the HCV E1 and E2 proteins were investigated in
a binding experiment as described for Fig. 3A. Pseudopar-
ticles containing the HCV envelope proteins bound to DC-
SIGN expressing cells about 3-fold more efficiently than to
control cells (Fig. 3B). In contrast, binding of pseudovirions
to LSECtin expressing cells was comparable to binding tocontrol cells (Fig. 3B), suggesting that the HCV E1 and E2
proteins are not recognized by LSECtin. Thus, LSECtin
exhibits a different ligand specificity compared to DC-
SIGN/R.
LSECtin binding to pathogens cannot be blocked by
mannan and depends on the presence of calcium
We next determined if differential ligand binding by DC-
SIGN/R and LSECtin is reflected by differences in
Fig. 3. LSECtin does not interact with HIV-1 and infectious pseudovirions bearing the HCV E1 and E2 proteins. (A) Binding and transmission of HIV-1 by
lectin expressing T-REx cells. T-REx cells were induced to express the indicated lectins, preincubated in the presence or absence of mannan and incubated for
3 h with replication-competent NL4-3 reporter virus harboring the luciferase gene in place of nef. Thereafter, the cells were washed and either processed to
analyze viral binding or transmission to target cells. Binding was assessed by lysing the cells in 1% Triton X-100 and quantification of bound antigen by p24-
antigen capture ELISA. Transmission was determined by cocultivation of virus pulsed cells with CEMx174 5.25 target cells and analysis of luciferase
production in the cultures 3 days after the start of the cocultivation. Results are shown as percent (%) HIV-1 binding (black bars) or transmission (white bars) by
control cells, which was set as 100%. Error bars indicate SD, comparable results were obtained in an independent experiment. (B) Binding of pseudovirions
harboring the HCV GP proteins to lectin expressing T-REx cells. The binding assay was carried out as described in the legend of panel A, except that HIV-1
pseudovirions harboring HCV E1 and E2 proteins in their envelope were used as input. The amount of bound virus is shown relative to the amount of input
virus. A representative experiment is shown, the results were confirmed in an independent experiment. Error bars indicate SD.
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the indicated carbohydrates at a final concentration of 100
Ag/ml and infected with ZEBOV-GP bearing pseudotypes.
Preincubation with d(+)glucose, l()fucose, N-acetylglu-
cosamine (Glc-NAc), N-acetylgalactosamine (Gal-Nac), and
methyl a-d-galacto-pyranoside (MetGal) had no appreci-
able effect on DC-SIGN/R- and LSECtin-mediated
enhancement of infection (Fig. 4A). In agreement with
published data (Geijtenbeek et al., 2000), preincubation of
target cells with mannan or mannose strongly reduced DC-
SIGN/R-mediated enhancement of ZEBOV-GP driven
infection (Fig. 4A and data not shown). In contrast, these
carbohydrates had no appreciable effect on LSECtin-
dependent augmentation of infectious cellular entry, indicat-
ing that LSECtin interactions with pathogens might not be
mediated through recognition of high-mannose glycans.
Complexation of calcium by the DC-SIGN/R and LSECtin
lectin domains has been shown to be important for
carbohydrate binding (Geijtenbeek et al., 2000; Liu et al.,
2004). Indeed, preincubation of LSECtin and DC-SIGN/R
expressing cells with 5 mM EGTA strongly diminished
ZEBOV-GP driven infection (Fig. 4B). In contrast, infec-
tious entry driven by VSV-G, which is not augmented by the
lectins tested (Fig. 2A), was only moderately reduced,
probably because of toxic effects of EGTA (Fig. 4B).
Similarly, the G1 subunit of ZEBOV-GP fused to human
immunoglobulin (Ig) bound efficiently to LSECtin express-
ing cells but not to control cells and binding could be
abrogated by preincubation with EGTA (Fig. 4C). Thus,
LSECtin requires calcium ions for function as an attachment
factor.N-linked glycosylation is required for surface expression of
LSECtin on transfected cells
LSECtin contains two consensus signals for N-linked
glycosylation, both located in the neck domain of the
protein. We assessed if these signals are utilized and if N-
linked glycosylation is required for expression of LSECtin
at the cell surface. DC-SIGN, LSECtin, and LSECtin
variants with mutated glycosylation signals were transiently
expressed in the presence or absence of tunicamycin, an
inhibitor of N-linked glycosylation, and expression was
analyzed by Western blot. Tunicamycin treatment aug-
mented the gel mobility of DC-SIGN, which is in agreement
with published results (Po¨hlmann et al., 2001a), and of
LSECtin, indicating that these proteins are modified by N-
linked glycosylation (Fig. 5A). Inactivation of the glyco-
sylation signal at amino acids 73–75 resulted in faster gel
migration compared to wt LSECtin, and gel mobility was
further increased upon addition of tunicamycin to the
culture medium, suggesting that both glycosylation signals
are utilized (Fig. 5A). In fact, inactivation of the second
glycosylation signal located at amino acids 159–161 also
augmented gel mobility, albeit a band with the size of wt
LSECtin was still detected. Upon mutation of both gly-
cosylation sites, a prominent band of the size of tunicamy-
cin-treated LSECtin was observed, further substantiating
that both asparagine 73 and 159 are modified by glycans.
Analysis of surface expression and attachment factor
function of the LSECtin variants with altered glycosylation
signals revealed that mutation of asparagine 73 alone
strongly reduced surface expression and consequently
Fig. 4. Inhibition of lectin-mediated enhancement of ZEBOV-GP driven infection by carbohydrates and EGTA. (A) Carbohydrate inhibition of ZEBOV-GP
mediated infection of lectin expressing cells. Lectin expression was induced on T-REx cells; the cells were incubated with the indicated carbohydrates
(100 Ag/ml final concentration) and infected with ZEBOV-GP harboring pseudotypes. A representative experiment performed in quadruplicates is shown,
error bars indicate SD. The results were confirmed in two independent experiments. (B) EGTA inhibition of ZEBOV-GP mediated infection of lectin
expressing cells. DC-SIGN and LSECtin expression was induced on T-REx cells, the cells treated with EGTA (5 mM final concentration) and infected
with pseudovirions harboring either ZEBOV-GP or VSV-G. Input viruses were normalized for comparable luciferase production upon infection of control
cells. The results are presented as fold inhibition compared to infection of target cells treated with PBS. A representative experiment is shown, error bars
indicate SD. Comparable results were obtained in an independent experiment. (C) EGTA inhibition of ZEBOV-GP binding to LSECtin. Induced control
cells (black line) or induced LSECtin T-REx cells (black area) were preincubated with PBS or EGTA, incubated with ZEBOV-GP-Ig fusion protein
concentrated from cellular supernatants, and ZEBOV-GP-Ig binding was detected with an antibody specific for the Fc portion of the fusion protein.
Reactivity is shown relative to untreated control cells incubated with secondary antibody (gray area). A representative experiment is shown, similar results
were obtained in an independent experiment.
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These results suggest that glycosylation of LSECtin, at least
in the context of 293T cells, is essential for efficient
expression on the cell surface.
The GPs of all EBOV subspecies functionally interact with
LSECtin, and LSECtin augments infection with
replication-competent ZEBOV
Engagement of cellular attachment factors might pro-
foundly impact EBOV tropism, especially at the early stages
of infection (Baribaud et al., 2002). However, the GPs of the
four EBOV subspecies bind to attachment factors with
differential efficiencies (Lin et al., 2003; Simmons et al.,
2003; Takada et al., 2004). Therefore, we asked if LSECtinaugments infectious entry driven by the GPs of all EBOV
subspecies. T-REx cells expressing DC-SIGN or LSECtin or
T-REx control cells were infected with infectivity normal-
ized pseudotypes bearing the GPs of the EBOV subspecies
Zaire, Sudan (SEBOV), Ivory Coast (ICEBOV), and Reston
(REBOV) (Fig. 6A). As observed previously (Alvarez et al.,
2002; Lin et al., 2003; Simmons et al., 2003), DC-SIGN
expression particularly enhanced infection driven by
ZEBOV- and REBOV-GP, whereas augmentation of entry
mediated by SEBOV- and ICEBOV-GP was somewhat less
pronounced. Similar results were obtained for LSECtin-
mediated enhancement of infection; however, LSECtin was
repeatedly more adept in enhancing ICEBOV-GP-dependent
infection when compared to DC-SIGN. Thus, LSECtin can
interact with the GPs of all EBOV subspecies with
Fig. 5. Glycosylation of LSECtin in transfected cells. (A) Inhibition of
N-linked glycosylation by tunicamycin. DC-SIGN, LSECtin, and
LSECtin variants with alterations in consensus signals for N-linked
glycosylation were transiently transfected into 293T cells, the cells
cultivated in the presence or absence of tunicamycin (1 Ag/ml) and
lectin expression was analyzed by Western blot 48 h after transfection.
The results were confirmed in three independent experiments. TM,
Tunicamycin. (B) Enhancement of ZEBOV-GP driven infection by
LSECtin variants with defective N-linked glycosylation signals. LSECtin
and the indicated LSECtin variants with defects in glycosylation signals
were transiently expressed in 293T cells and lectin expression and
enhancement of ZEBOV-GP driven infection analyzed in parallel.
Expression was determined by staining with a LSECtin-specific
antiserum and FACS analysis, while augmentation of ZEBOV-GP
driven infection was assessed as described in the legend of Fig. 2A.
Surface expression and augmentation of infection are shown relative to
pcDNA3 transfected control cells, which was set as 100%. The average
of three independent experiments performed in duplicates (surface
expression) or quadruplicates (infection) is shown, error bars indicate
standard error of the mean.
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viruses. Since lentiviral and filoviral particles differ in size
and shape and GP interactions with attachment factors
might depend on the nature of the viral particle on which
GPs are presented, we finally assessed if LSECtin expres-
sion also enhances infection by replication-competent
ZEBOV. T-REx cell lines were induced to express DC-
SIGN, LSECtin, or empty vector, inoculated with ZEBOV
and infected cells were detected by immunostaining (Fig.
6B). DC-SIGN and LSECtin expression enhanced ZEBOV
infection compared to control cells, indicating that both
lectins functionally interact with replication-competent
filovirus particles.Discussion
We demonstrated that LSECtin augments infectious entry
driven by filovirus GPs and SARS-CoV-S protein and
enhances infection by replication-competent ZEBOV. In
contrast to the attachment factors DC-SIGN/R, LSECtin
does not interact with HIV-1 and HCV GPs and GP binding
to LSECtin was not blocked by mannan, suggesting that
LSECtin has a different carbohydrate and ligand specificity
than DC-SIGN/R. Thus, LSECtin is a potent attachment
factor, which in concert with DC-SIGNR might concentrate
certain viral pathogens in liver and lymph nodes.
Engagement of LSECtin and related attachment factors
might be of particular relevance for filovirus infection.
Filoviruses exhibit an extremely broad cell tropism in vitro
(Wool-Lewis and Bates, 1998), and viral proteins can be
detected in many cell types and organs during the late stage
of infection (Geisbert et al., 2003a). In sharp contrast, the
viral tropism during the early stages of infection is quite
narrow. Thus, macrophages and DCs are early and sustained
target cells, and spleen and liver are among the first organs
infected (Geisbert et al., 2003a). The discrepancy between
the broad tropism late in infection and the limited range of
targets early in infection is unlikely to be due to differential
receptor expression, but might be explained by EBOV
engagement of attachment factors expressed on specific
target cells (Simmons et al., 2003). Thus, LSECtin and DC-
SIGNR on LSECs might capture and transmit virus to
adjacent hepatocytes and Kupffer cells, the latter known to
be early targets of filovirus infection (Geisbert et al., 2003a).
Capture of DHBV particles and transmission to adjacent
hepatocytes has been observed in infected animals (Breiner
et al., 2001), providing evidence that LSECs are capable of
promoting viral infection in trans. Endothelial cells are
targeted by ZEBOV, and in the context of lymph node and
liver sinusoids, LSECtin and DC-SIGNR might augment
direct infectious entry into this cell type (‘‘infection in cis’’).
In fact, endothelial cells of hepatic cortical sinusoids are the
first type of endothelial cells found to be infected in
cynomolgus monkeys experimentally inoculated with
ZEBOV (Geisbert et al., 2003b). Of note, the lectins DC-
SIGN, human macrophage C-type lectin specific for
galactose and Glc-NAc (hMGL), and asialoglycoprotein
receptor (ASGP-R) also augment filovirus infectious entry
in vitro (Alvarez et al., 2002; Becker et al., 1995; Lin et al.,
2003; Simmons et al., 2003; Takada et al., 2004) and might
promote infection of macrophages, DCs (DC-SIGN,
hMGL), and hepatocytes (ASGP-R) in vivo, providing
further evidence for a potential role of lectins in filovirus
tropism. Development of specific inhibitors and the analysis
of their impact on filovirus infection of primary cells are
required to assess the contribution of each lectin to viral
spread.
SARS is a respiratory disease (Peiris et al., 2003a), and a
role for LSECtin in SARS-CoV spread in patients is less
obvious. However, increasing evidence suggests that SARS-
Fig. 6. Interaction of LSECtin with the GPs of the EBOV subspecies and with replication-competent ZEBOV. (A) LSECtin enhances infection driven by the
GPs of the four EBOV subspecies. T-REx cells were induced to express the indicated lectins or control vector, inoculated with infectivity normalized
pseudotypes bearing the EBOV-GPs, VSV-G, or no GP (pcDNA3), and luciferase activity in cell lysates was determined as described in the legend to Fig. 2A.
(B) LSECtin expression enhances infection by replication-competent ZEBOV. T-REx cell lines were seeded in chamber slides, induced to express the indicated
lectins and infected with replication-competent ZEBOV. Cells producing ZEBOV antigen were detected by immunofluorescence at 24 h after infection.
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Pohlmann, 2004), but can be detected in several different
tissues and cell types (Ding et al., 2004; To et al., 2004)
including hepatocytes (Ding et al., 2004). Some hepatoma
cell lines were found to be susceptible to SARS-CoV-S
driven infection (Hofmann et al., 2004; Simmons et al.,
2004; Yang et al., 2004) and viral replication (Hofmann et
al., 2004), further underlining that SARS-CoV might
productively infect hepatocytes. In the light of these results,
it cannot be excluded that direct infection of liver tissue
might contribute to the altered levels of liver-specific
enzymes commonly observed in SARS-CoV-infected
patients (Ding et al., 2003; Lang et al., 2003; Peiris et al.,
2003b). Thus, similar as for filoviruses, it can be speculated
that LSECtin in conjunction with DC-SIGNR might
promote infection of LSECs and/or might target SARS-
CoV to adjacent hepatocytes, while SARS-CoVengagement
of DC-SIGN on DCs might facilitate viral dissemination
(Marzi et al., 2004; Yang et al., 2004). In contrast to the
efficient interaction of LSECtin with SARS-CoV and
filovirus GPs, no binding of HIV-1 and HCV GPs to
LSECtin expressed on 293T cells was detected. Thus,
LSECtin might not be involved in the interactions of lymph
node and liver sinusoidal endothelial cells with these
pathogens.
One possibility to evaluate the relative contributions of
LSECtin and DC-SIGNR to, e.g., LSEC interactions withZEBOV and SARS-CoV is to exploit differences in the
carbohydrate specificities of these lectins. Thus, DC-
SIGNR binds exclusively to high-mannose carbohydrates
(Feinberg et al., 2001; Guo et al., 2004), and lectin
engagement is blocked by preincubation with mannan
(Bashirova et al., 2001; Po¨hlmann et al., 2001c), a
mannose polymer obtained from the cell wall of yeast.
In contrast, mannan did not block ligand binding to
LSECtin, indicating that LSECtin might not recognize
mannose residues on the GPs tested. Therefore, mannan
and related sugars are suitable to inhibit DC-SIGNR but
not LSECtin. Notably, apart from mannose, fucose and
Glc-NAc also failed to prevent binding of ZEBOV-GP to
LSECtin, albeit these carbohydrates have previously been
shown to block binding of a mannosylated ligand to a
soluble LSECtin-Fc fusion protein (Liu et al., 2004). This
discrepancy might be due to differences in the exper-
imental systems used. Thus, carbohydrate inhibition of
binding of a mannosylated ligand to a soluble LSECtin-Fc
fusion protein was assessed in the previous study (Liu et
al., 2004), while we investigated the interaction of cellular
LSECtin, which was reported to form tetramers (Liu et al.,
2004), with multimeric GPs presented on the surface of
virions. Nevertheless, LSECtin interactions with ligand
were dependent on the presence of calcium, confirming
the previously reported classification of LSECtin as a C-
type lectin (Liu et al., 2004). Further analysis will be
T. Gramberg et al. / Virology 340 (2005) 224–236232required to define which carbohydrates on viral GPs are
bound by LSECtin and to investigate whether this lectin
recognizes other pathogens, which display the appropriate
glycosylation pattern.
LSECtin contains two consensus sites for N-linked
glycosylation located in the neck domain. Analysis of
LSECtin variants with altered glycosylation signals and
treatment of lectin expressing cells with tunicamycin, an
inhibitor of N-linked glycosylation, provided evidence that
both glycosylation sites are utilized and that glycosylation is
required for efficient cell surface expression and thus for
enhancement of ZEBOV-GP driven infection. In contrast,
tunicamycin treatment had relatively little effect on DC-
SIGN expression and attachment factor function (data not
shown), confirming a previous study, which demonstrated
that mutation of a unique, utilized N-linked glycosylation
signal in DC-SIGN does not affect interactions with HIV
(Po¨hlmann et al., 2001a). LSECtin and DC-SIGN/R might
also differ in regards to internalization and intracellular
trafficking upon ligand binding, a function known to be
important for DC-SIGN-mediated HIV transmission by DCs
(McDonald et al., 2003). Thus, the DC-SIGN/R cytoplasmic
tails harbor LL motifs which, at least in case of DC-SIGN,
might be required for efficient receptor internalization and
HIV transmission (Kwon et al., 2002). No such motif is
present in the cytoplasmic tail of LSECtin; however,
sequence analysis identified a YSKW sequence which
resembles a YSEI motif in the CD23 cytoplasmic tail
known to be involved in internalization of this lectin (Liu et
al., 2004). The role of internalization in DC-SIGN- and
LSECtin-mediated augmentation of viral infection in cis
remains to be determined.
In summary, LSECtin joins DC-SIGN/R, ASGP-R, and
hMGL as an attachment factor for ZEBOV, which might
modulate viral tropism in infected individuals. Ultimately,
the relevance of these factors for viral spread in vivo can
only be determined in animal models. A mouse model for
ZEBOV replication and pathogenesis has been established
(Bray et al., 1998). The characterization of mouse homo-
logues of LSECtin and DC-SIGN/R in vitro and the analysis
of their impact on viral tropism in infected animals are thus
of particular interest.Materials and methods
Cell culture
293T cells were propagated in Dulbecco’s modified
Eagle’s medium (DMEM) with 10% fetal bovine serum
(FBS), penicillin, and streptomycin. 293 T-REx cells
expressing DC-SIGN/R were described previously (Po¨hl-
mann et al., 2001a, 2001b) and maintained in DMEM
containing, 10% FBS, 50 Ag/ml zeocin (Invitrogen, CA,
USA), 2.5 Ag/ml blasticidin (Invitrogen, CA, USA),
penicillin, and streptomycin. A T-REx cell line expressingLSECtin was generated as described for DC-SIGN/R T-REx
cells (Po¨hlmann et al., 2001a). DC-SIGN/R and LSECtin
expression was induced by culturing the cells in medium
containing 0.1 Ag/ml doxycycline (SIGMA-Aldrich, Ger-
many). 293 T-REx parental cells were maintained in the
same medium as lectin expressing cell lines; however, no
zeocin was added. CEMx174 5.25 (Hsu et al., 2003) cells
were maintained in RPMI 1640 containing 10% FBS,
penicillin, and streptomycin. All cells were grown at 37 -C
and 5% CO2.
Plasmid construction and in vitro mutagenesis
For construction of LSECtin expression vectors, a frag-
ment encoding LSECtin was amplified from reverse-tran-
scribed liver RNA (Clontech) using the Superscript One Step
RT-PCR kit (Invitrogen, CA, USA) and cloned in the
pcDNA3.1Zeo vector (Invitrogen, California, USA) via
HindIII and XbaI. Expression plasmids encoding DC-SIGN
and DC-SIGNR were described previously (Po¨hlmann et al.,
2001a, 2001c). For regulated LSECtin expression, the open
reading frame was inserted in pcDNA4TO (Invitrogen, CA,
USA) using the restriction enzymes HindIII and XbaI. For
prokaryotic expression of LSECtin, a PCR-fragment span-
ning the entire LSECtin open reading frame was inserted into
pGEX6P1 via BamHI and XhoI (Amersham Biosciences,
UK) to yield the plasmid pGEX6P1-LSEC. LSECtin variants
with defects in two consensus signals for N-linked glyco-
sylation were generated by PCR mutagenesis employing




TGTCCTCAGCAGGTCGTGGCC) were employed to alter
the glycosylation signal NAS (amino acids 73 to 75), while
oligonucleotides 5V Lsec-mut 159ANS161 (GGAGGCCGT-
GAGGCTCCAGGCCAACTCCTGCGAGCCGTGCCCC)
and 3V Lsec-mut 159ANS161 (GGGGCACGGCTCGCAG-
GAGTTGGCCTGGAGCCTCACGGCCTCC) were used
to change the glycosylation signal 159NNS161 to
159ANS161. PCR-fragments encoding LSECtin variants
with altered glycosylation signals were cloned via HindIII
and XbaI into pcDNA3.1Zeo. An expression vector for
ZEBOV-GP protein fused to the Fc portion of human
immunoglobulin was obtained by inserting the sequence of
ZEBOVGP1 in the construct pAB61 (Birkmann et al., 2001).
All PCR-amplified sequences were confirmed by automated
sequence analysis. The GP expression plasmids employed
for the generation of pseudotyped viruses have been
described previously (Hofmann et al., 2004; Kolesnikova
et al., 2004; Simmons et al., 2003; Volchkov et al., 1998).
Antigens and antisera
A mouse monoclonal antibody (MAb) directed against
the AU1 antigenic tag was purchased from Covance
T. Gramberg et al. / Virology 340 (2005) 224–236 233Research Products, CA, USA. FITC-conjugated anti-mouse
IgG-Fcg and Cy5-conjugated anti-human secondary anti-
bodies were purchased from Jackson ImmunoResearch, PA,
USA and Dianova, Germany, respectively. Expression of a
GST-LSECtin fusion protein was induced in the E. coli
strain DH10B carrying the plasmid pGEX6P1-LSEC by
adding IPTG (1 mM) followed by purification of the fusion
protein employing Glutathione Sepharose 4B Beads (Amer-
sham Biosciences, UK). Anti LSECtin sera were obtained
by immunizing NMRI mice with the purified GST-LSECtin
fusion protein.
Expression analysis by flow cytometry
To assess cell surface expression of lectins, fluorescence-
activated cell sorting analysis (FACS) was performed.
Transiently transfected 293T cells or doxycycline-induced
T-REx cell lines were harvested, washed, and resuspended
in ice-cold FACS buffer (PBS with 3% FBS; 0.01% NaN3).
Approximately 2  105 cells were incubated with MAb
AU1 at 10 Ag/ml or sera from LSECtin-immunized mice
were diluted 1:100 in a total volume of 100 Al FACS buffer
for 45 min on ice. Cells were washed and incubated with
phycoerythrin-conjugated anti-mouse IgG at a final con-
centration of 5 Ag/ml for 45 min on ice. Thereafter, the cells
were washed, reconstituted in FACS buffer, and analyzed by
FACS employing a FACSCalibur flow cytometer (Becton
Dickinson). Analysis of LSECtin expression on LSEC was
carried out in an analogous fashion; however, cells were
detached from culture plates using non-enzymatic cell
dissocation solution (Sigma, UK).
Production of reporter viruses and infection assays
Simian immunodeficiency virus (SIV) pseudotypes were
generated by cotransfection of 293T cells with the indicated
GP expression plasmids in combination with the SIVmac 239
Denv Dnef Luc expression plasmid as described previously
(Kirchhoff et al., 1997). HIV-derived pseudotypes were
generated by cotransfection of 293T cells with GP expres-
sion plasmids and pNL4-3 ERLuc plasmid as described
previously (Connor et al., 1995). The production of
replication-competent HIV-1 NL4-3 reporter virus bearing
the luciferase gene in place of nef has been described
previously (Po¨hlmann et al., 2001a). The culture super-
natants were harvested 48 h after transfection, passed
through 0.4-Am-pore-size filters, aliquotted, and stored at
80 -C. To assess lectin-mediated enhancement of infec-
tion, 293T cells or T-REx cells induced to express the
indicated lectins were seeded onto 96-well plates at a
density of 1.0  104 and incubated with viral supernatants
normalized for comparable luciferase activity upon infection
of 293T cells. For neutralization assays, cells were
preincubated with serial dilutions of immune sera 3 h
before infection. For carbohydrate or EGTA inhibition
assays, cells were preincubated with 100 Ag/ml of theindicated carbohydrate (SIGMA-Aldrich, Germany) or
5 mM EGTA (SIGMA-Aldrich, Germany) 30 min before
infection. Generally, the medium was replaced 12 h after
infection and luciferase activity was determined 72 h after
infection with a commercially available kit as recommended
by the manufacturer (Promega, WI, USA).
Analysis of lectin-mediated binding and transmission of
reporter viruses
T-REx cells were seeded onto 96-well plates, induced to
express the indicated lectins and incubated with HIV
reporter viruses normalized for capsid protein (p24) content
by enzyme-linked immunosorbent assay (ELISA) (Murex;
Abbott Diagnostics, IL, USA). After a 3-h incubation at
37 -C, the cells were washed three times with PBS, and
either lysed in 1% Triton X-100 followed by quantification
of the amount of bound virus by p24-ELISA or cocultured
with CEMx174 5.25 cells (Hsu et al., 2003), and luciferase
activity in cell lysates was determined 72 h after
cocultivation.
ZEBOV infection and immunofluorescence analysis
ZEBOV was grown and passaged under biosafety level
4 conditions as described elsewhere (Modrof et al., 2002).
Infection of doxycycline-induced T-REx cell lines (6 
104 per well) with ZEBOV was performed in chamber
slides (Nunc, Germany). Cells were inoculated with viral
supernatant at a multiplicity of infection (MOI) of 1. After
1 h, viral supernatant was removed and cells were
maintained in DMEM, 2% FBS, and antibiotics for 24
h. For immunofluorescence analysis, cells were fixed for
24 h in 4% paraformaldehyde at 4 -C and permeabilized
with an ice-cold acetone–methanol mix. Cells were
incubated with an anti-ZEBOV goat immune serum
diluted 1:100, washed and incubated with FITC-conju-
gated F(abV)2Fragment anti-goat IgG (Dianova, Germany)
diluted 1:200 and DAPI (SIGMA-Adlrich, Germany)
1:10,000. Images were recorded using a fluorescence
microscope (Axiophot, Zeiss) and processed using Spot
software (Diagnostic Instruments, MI, USA).
Isolation and culture of intrahepatic endothelial cells
Primary intrahepatic endothelial cultures were isolated
from human liver tissue surplus to surgical requirements as
described previously (Lalor et al., 2002). Approximately
30 g of tissue was enzymatically digested using 2 mg/ml
collagenase Type 1A (Sigma,UK), filtered and further
purified by density gradient centrifugation using 25% (w/v)
metrizamide (Nycomed, Norway). Human sinusoidal
endothelial cells were extracted using negative magnetic
selection with antibody HEA125 (Progen Biotechnik,
Germany) to deplete biliary epithelial cells followed by
positive selection of endothelial cells with CD31 antibody
T. Gramberg et al. / Virology 340 (2005) 224–236234(Dako, UK) and Dynabeads conjugated with sheep anti-
mouse immunoglobulin (Dynal, UK). Endothelial cultures
(greater than 95% purity) were maintained in collagen-
coated flasks in complete medium (10% [v/v] human AB
serum; HD Supplies, UK, 10 ng/ml vascular endothelial
growth factor and 10 ng/ml hepatocyte growth factor
[R&D Systems, UK] both in human endothelial basal
medium supplemented with penicillin and streptomycin) at
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